Obsidian Therapeutics Inc.(OBX)

Biotechnology · Cambridge, MA

$13.62-0.22 (-1.59%)

Delayed quote: Oct 6, 2026, 12:55 PM EDT

EV/EBITDA Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/EBITDA ratio is N/A as of 2026-10-06T16:57:45.478Z.

Stored calculation inputs

Calculation as of: 2026-10-06T16:57:45.478Z.

Quote observation: 2026-10-06T16:55:09.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 14,166,330
Total debt: N/A
Cash: N/A
TTM operating EBITDA: N/A

FMP input reference: 0fde8dae4c5ae63ee7b35c7e6e46bba2fdf5d6d5db310b32cf0eb41a7e17e840

EV/Sales|P/E Ratio|EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

OBX EV/EBITDA Ratio Metrics

EV/EBITDA RATIO

N/A

OBX Competitors' EV/EBITDA Ratio

OBX

Obsidian Therapeutics Inc.

Current

Market Cap

$14.17M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

SINT

Sintx Technologies, Inc.

vs OBX

Market Cap

$13.92M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CTXR

Citius Pharmaceuticals, Inc.

vs OBX

Market Cap

$13.78M

EV/EBITDA Ratio

N/A

TTM Avg

116.01x

3Y Avg

116.01x

5Y Avg

116.01x

HIND

Vyome Holdings, Inc.

vs OBX

Market Cap

$13.66M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

PLSM

Pulsenmore Ltd. Ordinary Shares

vs OBX

Market Cap

$14.57M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

INAB

IN8bio, Inc.

vs OBX

Market Cap

$13.71M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

OPTH

Optimi Health Corp.

vs OBX

Market Cap

$13.51M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

KTTA

Pasithea Therapeutics Corp.

vs OBX

Market Cap

$14.98M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CLRB

Cellectar Biosciences, Inc.

vs OBX

Market Cap

$12.78M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

PASG

Passage Bio, Inc.

vs OBX

Market Cap

$13.24M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EV/EBITDA RATIO	TTM	3Y	5Y
Obsidian Therapeutics Inc. (OBX)	$14.17M	N/A	N/A	N/A	N/A
Sintx Technologies, Inc. (SINT)vs ›	$13.92M	N/A	N/A	N/A	N/A
Citius Pharmaceuticals, Inc. (CTXR)vs ›	$13.78M	N/A	116.01x	116.01x	116.01x
Vyome Holdings, Inc. (HIND)vs ›	$13.66M	N/A	N/A	N/A	N/A
Pulsenmore Ltd. Ordinary Shares (PLSM)vs ›	$14.57M	N/A	N/A	N/A	N/A
IN8bio, Inc. (INAB)vs ›	$13.71M	N/A	N/A	N/A	N/A
Optimi Health Corp. (OPTH)vs ›	$13.51M	N/A	N/A	N/A	N/A
Pasithea Therapeutics Corp. (KTTA)vs ›	$14.98M	N/A	N/A	N/A	N/A
Cellectar Biosciences, Inc. (CLRB)vs ›	$12.78M	N/A	N/A	N/A	N/A
Passage Bio, Inc. (PASG)vs ›	$13.24M	N/A	N/A	N/A	N/A

EV/EBITDA Ratio Formula & Definition

EV/EBITDA = Enterprise Value / EBITDA (TTM)

Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

EV/Sales P/E Ratio EBITDA All Metrics